Mechanisms of Resistance to Conventional Therapies for Osteosarcoma
Tóm tắt
Osteosarcoma (OS) is the most common primary bone tumor, mainly occurring in children and adolescents. Current standard therapy includes tumor resection associated with multidrug chemotherapy. However, patient survival has not evolved for the past decades. Since the 1970s, the 5-year survival rate is around 75% for patients with localized OS but dramatically drops to 20% for bad responders to chemotherapy or patients with metastases. Resistance is one of the biological processes at the origin of therapeutic failure. Therefore, it is necessary to better understand and decipher molecular mechanisms of resistance to conventional chemotherapy in order to develop new strategies and to adapt treatments for patients, thus improving the survival rate. This review will describe most of the molecular mechanisms involved in OS chemoresistance, such as a decrease in intracellular accumulation of drugs, inactivation of drugs, improved DNA repair, modulations of signaling pathways, resistance linked to autophagy, disruption in genes expression linked to the cell cycle, or even implication of the micro-environment. We will also give an overview of potential therapeutic strategies to circumvent resistance development.
Từ khóa
Tài liệu tham khảo
Lamoureux, 2007, Recent advances in the management of osteosarcoma and forthcoming therapeutic strategies, Expert Rev. Anticancer Ther., 7, 169, 10.1586/14737140.7.2.169
He, 2014, Review of the Molecular Pathogenesis of Osteosarcoma, Asian Pac. J. Cancer Prev., 15, 5967, 10.7314/APJCP.2014.15.15.5967
Marina, 2004, Biology and Therapeutic Advances for Pediatric Osteosarcoma, Oncologist, 9, 422, 10.1634/theoncologist.9-4-422
Sandberg, 2003, Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: Osteosarcoma and related tumors, Cancer Genet. Cytogenet., 145, 1, 10.1016/S0165-4608(03)00105-5
Klein, 2006, Osteosarcoma: Anatomic and histologic variants, Am. J. Clin. Pathol., 125, 555, 10.1309/UC6KQHLD9LV2KENN
Isakoff, 2015, Osteosarcoma: Current Treatment and a Collaborative Pathway to Success, J. Clin. Oncol., 33, 3029, 10.1200/JCO.2014.59.4895
Rejniak, 2015, Diagnostic assessment of osteosarcoma chemoresistance based on Virtual Clinical Trials, Med. Hypotheses, 85, 348, 10.1016/j.mehy.2015.06.015
ESMO/European Sarcoma Network Working Group (2014). Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol., 25, iii113–iii123.
Chen, 2020, Advances in differentiation therapy for osteosarcoma, Drug Discov. Today, 25, 497, 10.1016/j.drudis.2019.08.010
Anderson, 2003, Effectiveness of Radiotherapy for Osteosarcoma that Responds to Chemotherapy, Mayo Clin. Proc., 78, 145, 10.4065/78.2.145
Schwarz, 2009, The Role of Radiotherapy in Oseosarcoma, Cancer Treat. Res., 152, 147, 10.1007/978-1-4419-0284-9_7
Cubedo, 2010, Treatment of Osteosarcoma. A Review, Rev. Esp. Cir. Ortop. Traumatol., 54, 329
Saraf, 2018, Osteosarcoma: Accelerating Progress Makes for a Hopeful Future, Front. Oncol., 8, 4, 10.3389/fonc.2018.00004
Ferrari, 2007, Adjuvant and neoadjuvant combination chemotherapy for osteogenic sarcoma, Curr. Opin. Oncol., 19, 341, 10.1097/CCO.0b013e328122d73f
Mialou, 2005, Metastatic osteosarcoma at diagnosis: Prognostic factors and long-term outcom—The French pediatric experience, Cancer, 104, 1100, 10.1002/cncr.21263
Ottaviani, 2009, Functional, Psychosocial and Professional Outcomes in Long-Term Survivors of Lower-Extremity Osteosarcomas: Amputation Versus Limb Salvage, Cancer Treat. Res., 152, 421, 10.1007/978-1-4419-0284-9_23
Rosen, 1975, The rationale for multiple drug chemotherapy in the treatment of osteogenic sarcoma, Cancer, 35, 936, 10.1002/1097-0142(197503)35:3+<936::AID-CNCR2820350714>3.0.CO;2-B
Goorin, 2003, Presurgical Chemotherapy Compared with Immediate Surgery and Adjuvant Chemotherapy for Nonmetastatic Osteosarcoma: Pediatric Oncology Group Study POG-8651, J. Clin. Oncol., 21, 1574, 10.1200/JCO.2003.08.165
Wittig, 2002, Osteosarcoma: A multidisciplinary approach to diagnosis and treatment, Am. Fam. Physician, 65, 1123
Ando, 2013, Current Therapeutic Strategies and Novel Approaches in Osteosarcoma, Cancers, 5, 591, 10.3390/cancers5020591
Bielack, 2008, Bone Tumors in Adolescents and Young Adults, Curr. Treat. Options Oncol., 9, 67, 10.1007/s11864-008-0057-1
Holohan, 2013, Cancer drug resistance: An evolving paradigm, Nat. Rev. Cancer, 13, 714, 10.1038/nrc3599
Lippert, 2008, Intrinsic and Acquired Drug Resistance in Malignant Tumors. The main reason for therapeutic failure, Arzneimittelforschung, 58, 261
Wang, X. (2020, May 07). Drug Resistance and Combating Drug Resistance in Cancer. Available online: https://cdrjournal.com/article/view/3039.
Chou, 2006, Chemotherapy resistance in osteosarcoma: Current challenges and future directions, Expert Rev. Anticancer Ther., 6, 1075, 10.1586/14737140.6.7.1075
Lewis, 2007, Improvement in Histologic Response But Not Survival in Osteosarcoma Patients Treated With Intensified Chemotherapy: A Randomized Phase III Trial of the European Osteosarcoma Intergroup, J. Natl. Cancer Inst., 99, 112, 10.1093/jnci/djk015
Royen, 2013, Mechanisms of therapy resistance in osteosarcoma: A review, Oncol. Discov., 1, 8, 10.7243/2052-6199-1-8
Fotoohi, 2008, Mechanisms of antifolate resistance and methotrexate efficacy in leukemia cells, Leuk. Lymphoma, 49, 410, 10.1080/10428190701824569
He, 2014, Molecular mechanisms of chemoresistance in osteosarcoma (Review), Oncol. Lett., 7, 1352, 10.3892/ol.2014.1935
Takemura, 1997, Cellular and molecular mechanisms of resistance to antifolate drugs: New analogues and approaches to overcome the resistance, Int. J. Hematol., 66, 459, 10.1016/S0925-5710(97)00058-3
Jensen, 1997, Distinct roles for Sp1 and E2F sites in the growth/cell cycle regulation of the DHFR promoter, J. Cell. Biochem., 67, 24, 10.1002/(SICI)1097-4644(19971001)67:1<24::AID-JCB3>3.0.CO;2-Y
Goldman, 1985, The cellular pharmacology of methotrexate, Pharmacol. Ther., 28, 77, 10.1016/0163-7258(85)90083-X
Bertino, 1996, Resistance Mechanisms to Methotrexate in Tumors, Oncologist, 1, 223, 10.1634/theoncologist.1-4-223
Moscow, 1998, Methotrexate transport and resistance, Leuk. Lymphoma, 30, 215, 10.3109/10428199809057535
Bertino, 1993, Karnofsky memorial lecture. Ode to methotrexate, J. Clin. Oncol., 11, 5, 10.1200/JCO.1993.11.1.5
Wang, 2014, Relationship between RFC gene expression and intracellular drug concentration in methotrexate-resistant osteosarcoma cells, Genet. Mol. Res., 13, 5313, 10.4238/2014.July.24.10
Hattinger, 2003, Genomic imbalances associated with methotrexate resistance in human osteosarcoma cell lines detected by comparative genomic hybridization-based techniques, Eur. J. Cell Biol., 82, 483, 10.1078/0171-9335-00336
Flintoff, 2004, Functional analysis of altered reduced folate carrier sequence changes identified in osteosarcomas, Biochim. Biophys. Acta Mol. Basis Dis., 1690, 110, 10.1016/j.bbadis.2004.05.008
Ifergan, 2003, Reduced folate carrier protein expression in osteosarcoma, Cancer, 98, 1958, 10.1002/cncr.11741
Yang, 2003, Sequence alterations in the reduced folate carrier are observed in osteosarcoma tumor samples, Clin. Cancer Res., 9, 837
Serra, 2004, Analysis of dihydrofolate reductase and reduced folate carrier gene status in relation to methotrexate resistance in osteosarcoma cells, Ann. Oncol., 15, 151, 10.1093/annonc/mdh004
Yang, 2008, Polymorphisms and Methylation of the Reduced Folate Carrier in Osteosarcoma, Clin. Orthop. Relat. Res., 466, 2046, 10.1007/s11999-008-0323-3
Lilienthal, I., and Herold, N. (2020). Targeting Molecular Mechanisms Underlying Treatment Efficacy and Resistance in Osteosarcoma: A Review of Current and Future Strategies. Int. J. Mol. Sci., 21.
Memorial Sloan Kettering Cancer Center (2020, December 15). Phase I Study of High Dose Methotrexate with Simultaneous Trimetrexate and Leucovorin in Patients with Recurrent Osteosarcoma. Report No.: NCT00119301, Available online: https://clinicaltrials.gov/ct2/show/NCT00119301.
Sirotnak, 1984, New folate analogs of the 10-deaza-aminopterin series Basis for structural design and biochemical and pharmacologic properties, Cancer Chemother. Pharmacol., 12, 18
Pro, 2011, Pralatrexate in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results From the Pivotal PROPEL Study, J. Clin. Oncol., 29, 1182, 10.1200/JCO.2010.29.9024
Alberts, 2004, Efficacy and safety of liposomal anthracyclines in Phase I/II clinical trials, Semin. Oncol., 31, 53, 10.1053/j.seminoncol.2004.08.010
Gorlick, 2009, Novel therapeutic agents for osteosarcoma, Expert Rev. Anticancer Ther., 9, 511, 10.1586/era.09.7
Krishna, 2000, Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs, Eur. J. Pharm. Sci., 11, 265, 10.1016/S0928-0987(00)00114-7
Choi, 2005, ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal, Cancer Cell Int., 5, 30, 10.1186/1475-2867-5-30
Chen, 2016, Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade, Cancer Lett., 370, 153, 10.1016/j.canlet.2015.10.010
Amawi, 2019, ABC Transporter-Mediated Multidrug-Resistant Cancer, Adv. Exp. Med. Biol., 1141, 549, 10.1007/978-981-13-7647-4_12
Riordan, 1979, Purification of P-glycoprotein from plasma membrane vesicles of Chinese hamster ovary cell mutants with reduced colchicine permeability, J. Biol. Chem., 254, 12701, 10.1016/S0021-9258(19)86370-6
Li, 2015, Research progress on the multidrug resistance mechanisms of osteosarcoma chemotherapy and reversal, Tumor Biol., 36, 1329, 10.1007/s13277-015-3181-0
Robey, 2018, Revisiting the role of efflux pumps in multidrug-resistant cancer, Nat. Rev. Cancer, 18, 452, 10.1038/s41568-018-0005-8
Schinkel, 2003, Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: An overview, Adv. Drug Deliv. Rev., 55, 3, 10.1016/S0169-409X(02)00169-2
Kartner, 1983, Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines, Science, 221, 1285, 10.1126/science.6137059
Scotlandi, 1994, Pre-Treatment of human osteosarcoma cells with N-methylformamide enhances P-glycoprotein expression and resistance to doxorubicin, Int. J. Cancer, 58, 95, 10.1002/ijc.2910580116
Gomes, 2006, Multidrug resistance mediated by ABC transporters in osteosarcoma cell lines: mRNA analysis and functional radiotracer studies, Nucl. Med. Biol., 33, 831, 10.1016/j.nucmedbio.2006.07.011
Oda, 2000, Establishment of new multidrug-resistant human osteosarcoma cell lines, Oncol. Rep., 7, 859
Serra, 2006, May P-glycoprotein status be used to stratify high-grade osteosarcoma patients? Results from the Italian/Scandinavian Sarcoma Group 1 treatment protocol, Int. J. Oncol., 29, 1459
Hornicek, 2000, P-Glycoprotein Levels Predict Poor Outcome in Patients With Osteosarcoma, Clin. Orthop. Relat. Res., 373, 11, 10.1097/00003086-200004000-00003
Chan, 1997, P-glycoprotein Expression: Critical Determinant in the Response to Osteosarcoma Chemotherapy, J. Natl. Cancer Inst., 89, 1706, 10.1093/jnci/89.22.1706
Baldini, 1995, Expression of P-Glycoprotein in High-Grade Osteosarcomas in Relation to Clinical Outcome, N. Engl. J. Med., 333, 1380, 10.1056/NEJM199511233332103
Baldini, 1999, P-glycoprotein expression in osteosarcoma: A basis for risk-adapted adjuvant chemotherapy, J. Orthop. Res., 17, 629, 10.1002/jor.1100170502
Serra, 2003, Value of P-Glycoprotein and Clinicopathologic Factors as the Basis for New Treatment Strategies in High-Grade Osteosarcoma of the Extremities, J. Clin. Oncol., 21, 536, 10.1200/JCO.2003.03.144
Caronia, D., Patiño-Garcia, A., Peréz-Martínez, A., Pita, G., Moreno, L.T., Zalacain-Díez, M., Molina, B., Colmenero, I., Sierrasesúmaga, L., and Benítez, J.F. (2011). Effect of ABCB1 and ABCC3 Polymorphisms on Osteosarcoma Survival after Chemotherapy: A Pharmacogenetic Study. PLoS ONE, 6.
Park, 2001, The co-expression of p53 protein and P-glycoprotein is correlated to a poor prognosis in osteosarcoma, Int. Orthop., 24, 307, 10.1007/s002640000196
Serra, 1999, Relationship between P-glycoprotein expression and p53 status in high-grade osteosarcoma, Int. J. Oncol., 14, 301
Jensen, 2008, Immunohistochemical Estimates of Angiogenesis, Proliferative Activity, p53 Expression, and Multiple Drug Resistance Have No Prognostic Impact in Osteosarcoma: A Comparative Clinicopathological Investigation, Sarcoma, 2008, 1, 10.1155/2008/874075
Gorlick, 1999, Expression of HER2/erbB-2 Correlates With Survival in Osteosarcoma, J. Clin. Oncol., 17, 2781, 10.1200/JCO.1999.17.9.2781
Kumta, 2001, Clinical significance of P-glycoprotein immunohistochemistry and doxorubicin binding assay in patients with osteosarcoma, Int. Orthop., 25, 279, 10.1007/s002640100273
Pakos, 2003, The association of P-glycoprotein with response to chemotherapy and clinical outcome in patients with osteosarcoma. A meta-analysis, Cancer, 98, 581, 10.1002/cncr.11546
Zhao, 2014, Association between P-Glycoprotein expression and response to chemotherapy in patients with osteosarcoma: A systematic and meta-analysis, J. Cancer Res. Ther., 10, 206, 10.4103/0973-1482.145874
Schwartz, 2007, Multiple Drug Resistance in Osteogenic Sarcoma: INT0133 from the Children’s Oncology Group, J. Clin. Oncol., 25, 2057, 10.1200/JCO.2006.07.7776
Brambilla, 2011, P-glycoprotein binds to ezrin at amino acid residues 149–242 in the FERM domain and plays a key role in the multidrug resistance of human osteosarcoma, Int. J. Cancer, 130, 2824, 10.1002/ijc.26285
Khanna, 2004, The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis, Nat. Med., 10, 182, 10.1038/nm982
Yang, 2014, Prevention of multidrug resistance (MDR) in osteosarcoma by NSC23925, Br. J. Cancer, 110, 2896, 10.1038/bjc.2014.254
Lu, 2017, Tetrandrine prevents multidrug resistance in the osteosarcoma cell line, U-2OS, by preventing Pgp overexpression through the inhibition of NF-κB signaling, Int. J. Mol. Med., 39, 993, 10.3892/ijmm.2017.2895
Wu, 2017, Pleiotrophin promotes chemoresistance to doxorubicin in osteosarcoma by upregulating P-glycoprotein, Oncotarget, 8, 63857, 10.18632/oncotarget.19148
Liu, 2016, Targeting ABCB1 (MDR1) in multi-drug resistant osteosarcoma cells using the CRISPR-Cas9 system to reverse drug resistance, Oncotarget, 7, 83502, 10.18632/oncotarget.13148
Fanelli, 2016, Targeting ABCB1 and ABCC1 with their Specific Inhibitor CBT-1® can Overcome Drug Resistance in Osteosarcoma, Curr. Cancer Drug Targets, 16, 261, 10.2174/1568009616666151106120434
Jin, 2000, Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation, Proc. Natl. Acad. Sci. USA, 97, 6775, 10.1073/pnas.97.12.6775
Lee, 2017, DHFR and MDR1 upregulation is associated with chemoresistance in osteosarcoma stem-like cells, Oncol. Lett., 14, 171, 10.3892/ol.2017.6132
Marques da Costa, M.E., Marchais, A., Gomez-Brouchet, A., Job, B., Assoun, N., Daudigeos-Dubus, E., Fromigué, O., Santos, C., Geoerger, B., and Gaspar, N. (2019). In-Vitro and In-Vivo Establishment and Characterization of Bioluminescent Orthotopic Chemotherapy-Resistant Human Osteosarcoma Models in NSG Mice. Cancers, 11.
Li, 1995, Lack of functional retinoblastoma protein mediates increased resistance to antimetabolites in human sarcoma cell lines, Proc. Natl. Acad. Sci. USA, 92, 10436, 10.1073/pnas.92.22.10436
Sowers, 2003, mRNA expression levels of E2F transcription factors correlate with dihydrofolate reductase, reduced folate carrier, and thymidylate synthase mRNA expression in osteosarcoma, Mol. Cancer Ther., 2, 535
Hattinger, 2008, Mechanisms of gene amplification and evidence of coamplification in drug-resistant human osteosarcoma cell lines, Genes Chromosom. Cancer, 48, 289, 10.1002/gcc.20640
Song, 2010, Molecular mechanism of chemoresistance by miR-215 in osteosarcoma and colon cancer cells, Mol. Cancer, 9, 96, 10.1186/1476-4598-9-96
Bodley, 1989, DNA topoisomerase II-mediated interaction of doxorubicin and daunorubicin congeners with DNA, Cancer Res., 49, 5969
Minotti, 2004, Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity, Pharmacol. Rev., 56, 185, 10.1124/pr.56.2.6
Rajkumar, 2008, Multiple pathways are involved in drug resistance to doxorubicin in an osteosarcoma cell line, Anti Cancer Drugs, 19, 257, 10.1097/CAD.0b013e3282f435b6
Yang, 2016, Characterization of multidrug-resistant osteosarcoma sublines and the molecular mechanisms of resistance, Mol. Med. Rep., 14, 3269, 10.3892/mmr.2016.5590
Conklin, 2004, Chemotherapy-Associated Oxidative Stress: Impact on Chemotherapeutic Effectiveness, Integr. Cancer Ther., 3, 294, 10.1177/1534735404270335
Townsend, 2003, The importance of glutathione in human disease, Biomed. Pharmacother., 57, 145, 10.1016/S0753-3322(03)00043-X
Siddik, 2003, Cisplatin: Mode of cytotoxic action and molecular basis of resistance, Oncogene, 22, 7265, 10.1038/sj.onc.1206933
Kelland, 2000, Preclinical perspectives on platinum resistance, Drugs, 59, 1, 10.2165/00003495-200059004-00001
Goto, 2001, A novel single-nucleotide polymorphism in the 3′-untranslated region of the human dihydrofolate reductase gene with enhanced expression, Clin. Cancer Res., 7, 1952
Tew, 1996, Glutathione-associated enzymes in the human cell lines of the National Cancer Institute Drug Screening Program, Mol. Pharmacol., 50, 149
Tew, 1994, Glutathione-associated enzymes in anticancer drug resistance, Cancer Res., 54, 4313
Townsend, 2003, The role of glutathione-S-transferase in anti-cancer drug resistance, Oncogene, 22, 7369, 10.1038/sj.onc.1206940
Masanek, 1997, Messenger RNA expression of resistance proteins and related factors in human ovarian carcinoma cell lines resistant to doxorubicin, taxol and cisplatin, Anti Cancer Drugs, 8, 189, 10.1097/00001813-199702000-00010
Ban, 1996, Transfection of glutathione S-transferase (GST)-pi antisense complementary DNA increases the sensitivity of a colon cancer cell line to adriamycin, cisplatin, melphalan, and etoposide, Cancer Res., 56, 3577
Batist, 1986, Overexpression of a novel anionic glutathione transferase in multidrug-resistant human breast cancer cells, J. Biol. Chem., 261, 15544, 10.1016/S0021-9258(18)66748-1
Bai, 1996, Immunohistochemical expression of glutathione S-transferase-Pi can predict chemotherapy response in patients with nonsmall cell lung carcinoma, Cancer, 78, 416, 10.1002/(SICI)1097-0142(19960801)78:3<416::AID-CNCR6>3.0.CO;2-H
Pasello, 2008, Overcoming Glutathione S-Transferase P1–Related Cisplatin Resistance in Osteosarcoma, Cancer Res., 68, 6661, 10.1158/0008-5472.CAN-07-5840
Wei, 2006, Expression of MDR1 and GST-pi in osteosarcoma and soft tissue sarcoma and their correlation with chemotherapy resistance, Zhonghua Zhong Liu Za Zhi Chin. J. Oncol., 28, 445
Huang, 2007, Expression of human glutathione S-transferase P1 mediates the chemosensitivity of osteosarcoma cells, Mol. Cancer Ther., 6, 1610, 10.1158/1535-7163.MCT-06-0580
Komiya, 1998, Role of glutathione in cisplatin resistance in osteosarcoma cell lines, J. Orthop. Res., 16, 15, 10.1002/jor.1100160104
Shoieb, 1998, In vitro reversal of glutathione-S-transferase-mediated resistance in canine osteosarcoma (COS31) cells, In Vivo, 12, 455
Shoieb, 1997, Detection and significance of glutathione-S-transferase pi in osteogenic tumors of dogs, Int. J. Oncol., 10, 635
Bruheim, 2004, Human osteosarcoma xenografts and their sensitivity to chemotherapy, Pathol. Oncol. Res., 10, 133, 10.1007/BF03033741
Uozaki, 1997, Overexpression of resistance-related proteins (metallothioneins, glutathione-S-transferase pi, heat shock protein 27, and lung resistance-related protein) in osteosarcoma. Relationship with poor prognosis, Cancer, 79, 2336, 10.1002/(SICI)1097-0142(19970615)79:12<2336::AID-CNCR7>3.0.CO;2-J
Windsor, 2011, Germline genetic polymorphisms may influence chemotherapy response and disease outcome in osteosarcoma, Cancer, 118, 1856, 10.1002/cncr.26472
Zhang, 2012, Predictive Potential of Glutathione S-Transferase Polymorphisms for Prognosis of Osteosarcoma Patients on Chemotherapy, Asian Pac. J. Cancer Prev., 13, 2705, 10.7314/APJCP.2012.13.6.2705
Yang, 2012, Glutathione S-transferase P1 and DNA polymorphisms influence response to chemotherapy and prognosis of bone tumors, Asian Pac. J. Cancer Prev., 13, 5883, 10.7314/APJCP.2012.13.11.5883
Wang, 2014, The association of glutathione S-transferase polymorphisms in patients with osteosarcoma: Evidence from a meta-analysis, Eur. J. Cancer Care, 24, 417, 10.1111/ecc.12197
Liu, 2014, Predictive potential of ABCB1, ABCC3, and GSTP1 gene polymorphisms on osteosarcoma survival after chemotherapy, Tumor Biol., 35, 9897, 10.1007/s13277-014-1917-x
Petrilli, 2010, Glutathione S-transferase polymorphisms in osteosarcoma patients, Pharmacogenet. Genom., 20, 507, 10.1097/FPC.0b013e32833caa45
Yin, 2000, Glutathione S-transferase p elicits protection against H2O2-induced cell death via coordinated regulation of stress kinases, Cancer Res., 60, 4053
Lu, 2004, Dual effects of glutathione-S-transferase pi on As2O3 action in prostate cancer cells: Enhancement of growth inhibition and inhibition of apoptosis, Oncogene, 23, 3945, 10.1038/sj.onc.1207500
Pasello, 2011, Targeting glutathione-S transferase enzymes in musculoskeletal sarcomas: A promising therapeutic strategy, Anal. Cell. Pathol., 34, 131, 10.1155/2011/414985
Sau, 2012, Targeting GSTP1-1 induces JNK activation and leads to apoptosis in cisplatin-sensitive and -resistant human osteosarcoma cell lines, Mol. BioSyst., 8, 994, 10.1039/C1MB05295K
Chatterjee, 2017, Mechanisms of DNA damage, repair, and mutagenesis, Environ. Mol. Mutagen., 58, 235, 10.1002/em.22087
Fanelli, 2020, Cisplatin Resistance in Osteosarcoma: In vitro Validation of Candidate DNA Repair-Related Therapeutic Targets and Drugs for Tailored Treatments, Front. Oncol., 10, 331, 10.3389/fonc.2020.00331
Fishel, 2007, The DNA base excision repair protein Ape1/Ref-1 as a therapeutic and chemopreventive target, Mol. Asp. Med., 28, 375, 10.1016/j.mam.2007.04.005
Wang, 2004, Human apurinic endonuclease 1 (APE1) expression and prognostic significance in osteosarcoma: Enhanced sensitivity of osteosarcoma to DNA damaging agents using silencing RNA APE1 expression inhibition, Mol. Cancer Ther., 3, 679, 10.1158/1535-7163.679.3.6
Yang, 2010, APEX1 Gene Amplification and Its Protein Overexpression in Osteosarcoma: Correlation with Recurrence, Metastasis, and Survival, Technol. Cancer Res. Treat., 9, 161, 10.1177/153303461000900205
Yang, 2005, Alterations in the expression of the apurinic/apyrimidinic endonuclease-1/redox factor-1 (APE/Ref-1) in human melanoma and identification of the therapeutic potential of resveratrol as an APE/Ref-1 inhibitor, Mol. Cancer Ther., 4, 1923, 10.1158/1535-7163.MCT-05-0229
Luo, 2004, Inhibition of the human apurinic/apyrimidinic endonuclease (APE1) repair activity and sensitization of breast cancer cells to DNA alkylating agents with lucanthone, Anticancer Res., 24, 2127
Madhusudan, 2005, Isolation of a small molecule inhibitor of DNA base excision repair, Nucleic Acids Res., 33, 4711, 10.1093/nar/gki781
Seiple, 2007, Potent Inhibition of Human Apurinic/Apyrimidinic Endonuclease 1 by Arylstibonic Acids, Mol. Pharmacol., 73, 669, 10.1124/mol.107.042622
Dai, 2016, miR-513a-5p regulates radiosensitivity of osteosarcoma by targeting human apurinic/apyrimidinic endonuclease, Oncotarget, 9, 25414, 10.18632/oncotarget.11003
Liang, 2019, MicroRNA-765 sensitizes osteosarcoma cells to cisplatin via downregulating APE1 expression, OncoTargets Ther., 12, 7203, 10.2147/OTT.S194800
Wang, 2007, Vector-based Ape1 small interfering RNA enhances the sensitivity of human osteosarcoma cells to endostatin in vivo, Cancer Sci., 98, 1993, 10.1111/j.1349-7006.2007.00616.x
Park, 2018, The PARP inhibitor olaparib potentiates the effect of the DNA damaging agent doxorubicin in osteosarcoma, J. Exp. Clin. Cancer Res., 37, 107, 10.1186/s13046-018-0772-9
National Cancer Institute (NCI) (2020, December 20). NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)-Phase 2 Subprotocol of Olaparib in Patients With Tumors Harboring Defects in DNA Damage Repair Genes. Report No.: NCT03233204, Available online: https://clinicaltrials.gov/ct2/show/NCT03233204.
Janeway, K. (2020, December 20). Phase II Trial of Olaparib in Combination with Ceralasertib in Patients With Recurrent Osteosarcoma. Report No.: NCT04417062, Available online: https://clinicaltrials.gov/ct2/show/NCT04417062.
2013, Nucleotide Excision Repair in Eukaryotes, Cold Spring Harb. Perspect. Biol., 5, a012609
Hattinger, 2015, Excision repair cross-complementation group 1 protein expression predicts survival in patients with high-grade, non-metastatic osteosarcoma treated with neoadjuvant chemotherapy, Histopathology, 67, 338, 10.1111/his.12653
Nathrath, 2002, Expression of genes of potential importance in the response to chemotherapy in osteosarcoma patients, Klin. Padiatr., 214, 230, 10.1055/s-2002-33189
Li, 2007, Expressions of ERCC2 and ERCC4 genes in osteosarcoma and peripheral blood lymphocytes and their clinical significance, Beijing Da Xue Xue Bao, 39, 467
Caronia, 2009, Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients, Pharmacogenom. J., 9, 347, 10.1038/tpj.2009.19
Hao, 2012, Association of four ERCC1 and ERCC2 SNPs with survival of bone tumour patients, Asian Pac. J. Cancer Prev., 13, 3821, 10.7314/APJCP.2012.13.8.3821
Liu, 2017, Meta-analysis showing that ERCC1 polymorphism is predictive of osteosarcoma prognosis, Oncotarget, 8, 62769, 10.18632/oncotarget.19370
Obiedat, 2018, The effect of ERCC1 and ERCC2 gene polymorphysims on response to cisplatin based therapy in osteosarcoma patients, BMC Med. Genet., 19, 1, 10.1186/s12881-018-0627-4
DeChant, 2003, Identification of drug-regulated genes in osteosarcoma cells, Int. J. Cancer, 105, 636, 10.1002/ijc.11135
Liebermann, 1995, Molecular controls of growth arrest and apoptosis: p53-dependent and independent pathways, Oncogene, 11, 199
Overholtzer, 2003, The presence of p53 mutations in human osteosarcomas correlates with high levels of genomic instability, Proc. Natl. Acad. Sci. USA, 100, 11547, 10.1073/pnas.1934852100
Wong, 2007, p53-R273H gains new function in induction of drug resistance through down-regulation of procaspase-3, Mol. Cancer Ther., 6, 1054, 10.1158/1535-7163.MCT-06-0336
Sato, 2000, Enhancement of drug-induced apoptosis by antisense oligodeoxynucleotides targeted against Mdm2 and p21WAF1/CIP1, Anticancer Res., 20, 837
Asada, 2000, De novo deletions of p53 gene and wild-type p53 correlate with acquired cisplatin-resistance in human osteosarcoma OST cell line, Anticancer Res., 19, 5131
Tsuchiya, 2000, Sensitization and caffeine potentiation of cisplatin cytotoxicity resulting from introduction of wild-type p53 gene in human osteosarcoma, Anticancer Res., 20, 235
Fan, 1999, Modulation of Cisplatinum Cytotoxicity by p53: Effect of p53-Mediated Apoptosis and DNA Repair, Mol. Pharmacol., 56, 966, 10.1124/mol.56.5.966
Song, 2009, Mechanism of chemoresistance mediated by miR-140 in human osteosarcoma and colon cancer cells, Oncogene, 28, 4065, 10.1038/onc.2009.274
Goto, 1998, Association of Loss of Heterozygosity at the p53 Locus with Chemoresistance in Osteosarcomas, Jpn. J. Cancer Res., 89, 539, 10.1111/j.1349-7006.1998.tb03295.x
Ferrari, 2004, Evaluation of P-glycoprotein, HER-2/ErbB-2, p53, and Bcl-2 in primary tumor and metachronous lung metastases in patients with high-grade osteosarcoma, Cancer, 100, 1936, 10.1002/cncr.20151
Rossner, 2008, Mutations in p53, p53 protein overexpression and breast cancer survival, J. Cell. Mol. Med., 13, 3847, 10.1111/j.1582-4934.2008.00553.x
Pakos, 2004, Prognostic significance of TP53 tumor suppressor gene expression and mutations in human osteosarcoma: A meta-analysis, Clin. Cancer Res., 10, 6208, 10.1158/1078-0432.CCR-04-0246
Wunder, 2005, TP53 Mutations and Outcome in Osteosarcoma: A Prospective, Multicenter Study, J. Clin. Oncol., 23, 1483, 10.1200/JCO.2005.04.074
Hata, 2015, The BCL-2 family: Key mediators of the apoptotic response to targeted anti-cancer therapeutics, Cancer Discov., 5, 475, 10.1158/2159-8290.CD-15-0011
Reed, 1997, Double identity for proteins of the Bcl-2 family, Nat. Cell Biol., 387, 773
Zhao, 2009, Enhanced chemosensitivity of drug-resistant osteosarcoma cells by lentivirus-mediated Bcl-2 silencing, Biochem. Biophys. Res. Commun., 390, 642, 10.1016/j.bbrc.2009.10.020
Eliseev, 2008, Runx2-mediated activation of the Bax gene increases osteosarcoma cell sensitivity to apoptosis, Oncogene, 27, 3605, 10.1038/sj.onc.1211020
2003, Antisense to apoptosis inhibitors facilitates chemotherapy and TRAIL-induced death signaling, Ann. N. Y. Acad. Sci., 1002, 90, 10.1196/annals.1281.019
Zhang, 2000, Role of BAX in the Apoptotic Response to Anticancer Agents, Science, 290, 989, 10.1126/science.290.5493.989
Wu, 2012, Expressions of p53, c-MYC, BCL-2 and apoptotic index in human osteosarcoma and their correlations with prognosis of patients, Cancer Epidemiol., 36, 212, 10.1016/j.canep.2011.08.002
Nedelcu, 2007, Livin and Bcl-2 expression in high-grade osteosarcoma, J. Cancer Res. Clin. Oncol., 134, 237, 10.1007/s00432-007-0276-z
Konstadoulakis, 2008, Prognostic value of bax, bcl-2, and p53 staining in primary osteosarcoma, J. Surg. Oncol., 97, 259, 10.1002/jso.20913
Patatsos, 2018, Pre-clinical evaluation of proteasome inhibitors for canine and human osteosarcoma, Vet. Comp. Oncol., 16, 544, 10.1111/vco.12413
Lemmon, 2010, Cell Signaling by Receptor Tyrosine Kinases, Cell, 141, 1117, 10.1016/j.cell.2010.06.011
Pignochino, 2009, Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways, Mol. Cancer, 8, 118, 10.1186/1476-4598-8-118
Hughes, 2004, Cell Surface Expression of Epidermal Growth Factor Receptor and Her-2 with Nuclear Expression of Her-4 in Primary Osteosarcoma, Cancer Res., 64, 2047, 10.1158/0008-5472.CAN-03-3096
Zhou, 2011, VEGF and EMMPRIN expression correlates with survival of patients with osteosarcoma, Surg. Oncol., 20, 13, 10.1016/j.suronc.2009.09.002
Wu, 2019, Transferrin receptor-1 and VEGF are prognostic factors for osteosarcoma, J. Orthop. Surg. Res., 14, 1, 10.1186/s13018-019-1301-z
Ebb, 2012, Phase II Trial of Trastuzumab in Combination With Cytotoxic Chemotherapy for Treatment of Metastatic Osteosarcoma With Human Epidermal Growth Factor Receptor 2 Overexpression: A Report From the Children’s Oncology Group, J. Clin. Oncol., 30, 2545, 10.1200/JCO.2011.37.4546
Maris, 2008, Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program, Pediatr. Blood Cancer, 50, 581, 10.1002/pbc.21232
MacEwen, 2004, IGF-1 receptor contributes to the malignant phenotype in human and canine osteosarcoma, J. Cell. Biochem., 92, 77, 10.1002/jcb.20046
Hassan, 2011, Cell surface receptor expression patterns in osteosarcoma, Cancer, 118, 740, 10.1002/cncr.26339
Wang, 2011, Increased expression of insulin-like growth factor-1 receptor is correlated with tumor metastasis and prognosis in patients with osteosarcoma, J. Surg. Oncol., 105, 235, 10.1002/jso.22077
Luk, 2011, IGF1R-Targeted Therapy and Its Enhancement of Doxorubicin Chemosensitivity in Human Osteosarcoma Cell Lines, Cancer Investig., 29, 521, 10.3109/07357907.2011.606252
Rettew, 2012, Multiple receptor tyrosine kinases promote the in vitro phenotype of metastatic human osteosarcoma cell lines, Oncogenesis, 1, e34, 10.1038/oncsis.2012.34
Anderson, 2016, A phase II study of clinical activity of SCH 717454 (robatumumab) in patients with relapsed osteosarcoma and Ewing sarcoma, Pediatr. Blood Cancer, 63, 1761, 10.1002/pbc.26087
Chitnis, 2008, The Type 1 Insulin-Like Growth Factor Receptor Pathway, Clin. Cancer Res., 14, 6364, 10.1158/1078-0432.CCR-07-4879
Analysis of Aberrant Signal Transduction Pathways in Osteosarcoma Cell Lines (2020, November 08). Cancer Research. Available online: https://cancerres.aacrjournals.org/content/65/9_Supplement/1075.2.
Adamopoulos, 2016, Deciphering signaling networks in osteosarcoma pathobiology, Exp. Biol. Med., 241, 1296, 10.1177/1535370216648806
Kuijjer, M.L., van den Akker, B.E., Hilhorst, R., Mommersteeg, M., Buddingh, E.P., Serra, M., Buerger, H., Hogendoorn, P.C., and Cleton-Jansen, A.-M. (2014). Kinome and mRNA expression profiling of high-grade osteosarcoma cell lines implies Akt signaling as possible target for therapy. BMC Med. Genom., 7.
2009, Targeting the mTOR Signaling Network for Cancer Therapy, J. Clin. Oncol., 27, 2278, 10.1200/JCO.2008.20.0766
Gordon, 2008, Evaluation of the mammalian target of rapamycin pathway and the effect of rapamycin on target expression and cellular proliferation in osteosarcoma cells from dogs, Am. J. Vet. Res., 69, 1079, 10.2460/ajvr.69.8.1079
Gazitt, 1992, Targeted therapy of human osteosarcoma with 17AAG or rapamycin: Characterization of induced apoptosis and inhibition of mTOR and Akt/MAPK/Wnt pathways, Int. J. Oncol., 34, 551
Wan, 2005, Rapamycin Inhibits Ezrin-Mediated Metastatic Behavior in a Murine Model of Osteosarcoma, Cancer Res., 65, 2406, 10.1158/0008-5472.CAN-04-3135
Houghton, 2011, Initial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing program, Pediatr. Blood Cancer, 58, 191, 10.1002/pbc.22935
Chandhanayingyong, 2012, MAPK/ERK Signaling in Osteosarcomas, Ewing Sarcomas and Chondrosarcomas: Therapeutic Implications and Future Directions, Sarcoma, 2012, e404810, 10.1155/2012/404810
Cai, 2014, Wnt Pathway in Osteosarcoma, from Oncogenic to Therapeutic, J. Cell. Biochem., 115, 625, 10.1002/jcb.24708
Vijayakumar, 2011, High-Frequency Canonical Wnt Activation in Multiple Sarcoma Subtypes Drives Proliferation through a TCF/β-Catenin Target Gene, CDC25A, Cancer Cell, 19, 601, 10.1016/j.ccr.2011.03.010
Leow, 2009, Antitumor activity of natural compounds, curcumin and PKF118-310, as Wnt/β-catenin antagonists against human osteosarcoma cells, Investig. New Drugs, 28, 766, 10.1007/s10637-009-9311-z
Guo, 2008, Dominant Negative LRP5 Decreases Tumorigenicity and Metastasis of Osteosarcoma in an Animal Model, Clin. Orthop. Relat. Res., 466, 2039, 10.1007/s11999-008-0344-y
Kansara, 2009, Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in mice, J. Clin. Investig., 119, 837, 10.1172/JCI37175
Danieau, G., Morice, S., Redini, F., Verrecchia, F., and Le Royer, B.B. (2019). New Insights about the Wnt/β-Catenin Signaling Pathway in Primary Bone Tumors and Their Microenvironment: A Promising Target to Develop Therapeutic Strategies?. Int. J. Mol. Sci., 20.
Marion, 2012, Targeted inhibition of T-cell factor activity promotes syndecan-2 expression and sensitization to doxorubicin in osteosarcoma cells and bone tumors in mice, J. Bone Miner. Res., 27, 2118, 10.1002/jbmr.1650
Jiang, 2015, TRIM37 promoted the growth and migration of the pancreatic cancer cells, Tumor Biol., 37, 2629, 10.1007/s13277-015-4078-7
Tao, 2017, TRIM37 promotes tumor cell proliferation and drug resistance in pediatric osteosarcoma, Oncol. Lett., 14, 6365
Fang, 2018, Targeting the Wnt/β-catenin pathway in human osteosarcoma cells, Oncotarget, 9, 36780, 10.18632/oncotarget.26377
Krishnamurthy, 2018, Targeting the Wnt/beta-catenin pathway in cancer: Update on effectors and inhibitors, Cancer Treat. Rev., 62, 50, 10.1016/j.ctrv.2017.11.002
Harb, 2019, Recent Development of Wnt Signaling Pathway Inhibitors for Cancer Therapeutics, Curr. Oncol. Rep., 21, 12, 10.1007/s11912-019-0763-9
Degenhardt, 2006, Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis, Cancer Cell, 10, 51, 10.1016/j.ccr.2006.06.001
Maiuri, 2007, Kroemer GSelf-eating and self-killing: Crosstalk between autophagy and apoptosis, Nat. Rev. Mol. Cell Biol., 8, 741, 10.1038/nrm2239
Kim, 2013, Cytoprotective role of autophagy during paclitaxel-induced apoptosis in Saos-2 osteosarcoma cells, Int. J. Oncol., 42, 1985, 10.3892/ijo.2013.1884
Zhang, 2009, Expression of Beclin1 in osteosarcoma and the effects of down-regulation of autophagy on the chemotherapeutic sensitivity, J. Huazhong Univ. Sci. Technol. Med. Sci., 29, 737, 10.1007/s11596-009-0613-3
Coupienne, 2011, RIP3 expression induces a death profile change in U2OS osteosarcoma cells after 5-ALA-PDT, Lasers Surg. Med., 43, 557, 10.1002/lsm.21088
Tang, 2010, HMGB1 release and redox regulates autophagy and apoptosis in cancer cells, Oncogene, 29, 5299, 10.1038/onc.2010.261
Huang, 2012, Targeting HMGB1-mediated autophagy as a novel therapeutic strategy for osteosarcoma, Autophagy, 8, 275, 10.4161/auto.8.2.18940
Huang, 2012, HMGB1 Promotes Drug Resistance in Osteosarcoma, Cancer Res., 72, 230, 10.1158/0008-5472.CAN-11-2001
Yang, 2014, High-mobility group nucleosome-binding domain 5 increases drug resistance in osteosarcoma through upregulating autophagy, Tumor Biol. J. Int. Soc. Oncodev. Biol. Med., 35, 6357, 10.1007/s13277-014-1833-0
Xiao, 2018, HSP90AA1-mediated autophagy promotes drug resistance in osteosarcoma, J. Exp. Clin. Cancer Res., 37, 201, 10.1186/s13046-018-0880-6
Amaravadi, 2007, Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma, J. Clin. Investig., 117, 326, 10.1172/JCI28833
Carew, 2009, Autophagy inhibition enhances vorinostat-induced apoptosis via ubiquitinated protein accumulation, J. Cell. Mol. Med., 14, 2448, 10.1111/j.1582-4934.2009.00832.x
Shen, 2013, Chloroquine blocks the autophagic process in cisplatin-resistant osteosarcoma cells by regulating the expression of p62/SQSTM1, Int. J. Mol. Med., 32, 448, 10.3892/ijmm.2013.1399
Liu, 2017, Effect of rapamycin and chloroquine on osteosarcoma, Zhonghua Yi Xue Za Zhi, 97, 1510
Senthebane, D.A., Rowe, A., Thomford, N.E., Shipanga, H., Munro, D., Al Mazeedi, M.A.M., Almazyadi, H.A.M., Kallmeyer, K., Dandara, C., and Pepper, M.S. (2017). The Role of Tumor Microenvironment in Chemoresistance: To Survive, Keep Your Enemies Closer. Int. J. Mol. Sci., 18.
Vinogradov, 2012, Cancer stem cells and drug resistance: The potential of nanomedicine, Nanomedicine, 7, 597, 10.2217/nnm.12.22
Liu, 2011, Cancer stem cells in osteosarcoma: Recent progress and perspective, Acta Oncol., 50, 1142, 10.3109/0284186X.2011.584553
Zhang, 2013, Transforming Growth Factor β1 Signal is Crucial for Dedifferentiation of Cancer Cells to Cancer Stem Cells in Osteosarcoma, Stem Cells, 31, 433, 10.1002/stem.1298
Gibbs, 2005, Stem-Like Cells in Bone Sarcomas: Implications for Tumorigenesis, Neoplasia, 7, 967, 10.1593/neo.05394
Tirino, V., Desiderio, V., d’Aquino, R., De Francesco, F., Pirozzi, G., Graziano, A., Galderisi, U., Cavaliere, C., de Rosa, A., and Papaccio, G. (2008). Detection and characterization of CD133+ cancer stem cells in human solid tumours. PLoS ONE, 3.
Santulli, 2009, Identification and expansion of human osteosarcoma-cancer-stem cells by long-term 3-aminobenzamide treatment, J. Cell. Physiol., 219, 301, 10.1002/jcp.21667
Martins-Neves, S.R., Lopes, Á.O., do Carmo, A., Paiva, A.A., Simões, P.C., Abrunhosa, A.J., and Gomes, C.M.F. (2012). Therapeutic implications of an enriched cancer stem-like cell population in a human osteosarcoma cell line. BMC Cancer, 12.
Fujii, 2009, Sphere-forming stem-like cell populations with drug resistance in human sarcoma cell lines, Int. J. Oncol., 34, 1381
Honoki, 2010, Possible involvement of stem-like populations with elevated ALDH1 in sarcomas for chemotherapeutic drug resistance, Oncol. Rep., 24, 501, 10.3892/or_00000885
Chan, 2013, Pharmacological Inactivation of Skp2 SCF Ubiquitin Ligase Restricts Cancer Stem Cell Traits and Cancer Progression, Cell, 154, 556, 10.1016/j.cell.2013.06.048
Ding, 2018, S-phase kinase-associated protein 2 is involved in epithelial-mesenchymal transition in methotrexate-resistant osteosarcoma cells, Int. J. Oncol., 52, 1841
Cheng, 2016, Nitidine chloride suppresses epithelial-to-mesenchymal transition in osteosarcoma cell migration and invasion through Akt/GSK-3β/Snail signaling pathway, Oncol. Rep., 36, 1023, 10.3892/or.2016.4846
Kolb, 2003, Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma, Cancer, 98, 832, 10.1002/cncr.11563